HUGroup Holdings (JP:4544)
:4544
Want to see JP:4544 full AI Analyst Report?
Top Page
HUGroup Holdings
(4544)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥3,486.00
▼(-6.52% Downside)
Action:Reiterated
Date:05/15/26
The score is driven primarily by solid cash-flow resilience and manageable leverage, tempered by volatile profitability and a notable FY2026 revenue decline. Valuation is supportive (low P/E and ~3.9% yield), while technical indicators are mixed with negative MACD and price below the 200-day average.
Positive Factors
Consistent cash generation
HUGroup has repeatedly generated positive operating and free cash flow, including through a loss year, and delivered ~¥19.2B FCF in FY2026. Durable cash generation supports reinvestment, debt reduction, and dividend capacity, providing financial flexibility over the next 2–6 months.
Negative Factors
Volatile profitability
Profitability has been inconsistent: strong margins in FY2022–FY2023 gave way to a FY2024 loss and only modest recovery later. Persistent margin volatility undermines earnings predictability and could constrain reinvestment or dividend stability if structural pressures persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent cash generation
HUGroup has repeatedly generated positive operating and free cash flow, including through a loss year, and delivered ~¥19.2B FCF in FY2026. Durable cash generation supports reinvestment, debt reduction, and dividend capacity, providing financial flexibility over the next 2–6 months.
Read all positive factors
HUGroup Holdings (4544) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥191.69B
Dividend Yield3.72%
Average Volume (3M)243.85K
Price to Earnings (P/E)27.1
Beta (1Y)0.35
Revenue Growth1.78%
EPS Growth153.14%
CountryJP
Employees5,295
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)123.02
Shares Outstanding57,492,320
10 Day Avg. Volume223,460
30 Day Avg. Volume243,853
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.30
Price to Sales (P/S)0.72
P/FCF Ratio9.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,820.00Price Target Upside2.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)106.08
Revenue Forecast (FY)¥256.56B
HUGroup Holdings Business Overview & Revenue Model
Company Description
H.U. Group Holdings, Inc., through its subsidiaries, provides laboratory testing products and services in Japan. The company offers lab testing and its related services to medical institutions; self-medication services; food, environment, and cosm...
How the Company Makes Money
HUGroup Holdings primarily earns revenue by providing clinical laboratory testing services on a fee-for-service basis. This typically includes (1) routine and specialized diagnostic tests where specimens are collected by healthcare providers and t...
HUGroup Holdings Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
67
Positive
Cash Flow
74
Positive
| Breakdown | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 247.36B | 243.03B | 236.95B | 260.91B | 272.94B |
| Gross Profit | 70.77B | 67.20B | 63.23B | 89.92B | 111.80B |
| EBITDA | 26.54B | 24.55B | 13.65B | 42.97B | 56.34B |
| Net Income | 6.82B | 2.76B | -7.55B | 15.68B | 29.60B |
Balance Sheet | |||||
| Total Assets | 267.47B | 279.58B | 295.36B | 301.76B | 288.60B |
| Cash, Cash Equivalents and Short-Term Investments | 48.10B | 40.88B | 39.95B | 44.19B | 46.49B |
| Total Debt | 74.33B | 86.65B | 81.94B | 77.16B | 73.00B |
| Total Liabilities | 129.99B | 142.28B | 152.85B | 151.71B | 148.41B |
| Stockholders Equity | 137.41B | 137.12B | 142.50B | 150.05B | 140.18B |
Cash Flow | |||||
| Free Cash Flow | 19.21B | 20.88B | 4.18B | 18.30B | 31.50B |
| Operating Cash Flow | 21.57B | 24.96B | 16.55B | 32.53B | 55.23B |
| Investing Cash Flow | 11.34B | -18.96B | -16.05B | -29.58B | -30.86B |
| Financing Cash Flow | -26.39B | -5.30B | -5.78B | -5.76B | -21.73B |
HUGroup Holdings Technical Analysis
Positive
3729.00
Price Trends
3176.15
Positive
3184.42
Positive
3339.03
Positive
Market Momentum
28.37
Negative
64.52
Neutral
83.69
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4544, the sentiment is Positive. The current price of 3729 is above the 20-day moving average (MA) of 3191.45, above the 50-day MA of 3176.15, and above the 200-day MA of 3339.03, indicating a bullish trend. The MACD of 28.37 indicates Negative momentum. The RSI at 64.52 is Neutral, neither overbought nor oversold. The STOCH value of 83.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4544.
HUGroup Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥204.51B | 12.51 | ― | 2.35% | 7.84% | 17.59% | |
68 Neutral | ¥105.26B | 25.57 | ― | 2.47% | 2.70% | -4.93% | |
66 Neutral | ¥191.69B | 27.14 | 2.65% | 3.72% | 1.78% | 153.14% | |
64 Neutral | ¥174.89B | 13.85 | 9.53% | 2.19% | 5.89% | -9.94% | |
62 Neutral | ¥104.64B | 13.29 | ― | 0.25% | 9.94% | 15.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥71.99B | 67.53 | 5.76% | ― | 23.30% | -56.05% |
* Healthcare Sector Average
JP:4544
HUGroup Holdings
3,357.00
397.07
13.41%
JP:3360
Ship Healthcare Holdings
2,009.50
112.71
5.94%
JP:4480
Medley
2,199.00
-801.00
-26.70%
JP:3148
Create SD Holdings Co., Ltd.
3,235.00
151.22
4.90%
JP:6197
Solasto Corp.
1,111.00
704.15
173.07%
JP:9267
Genky DrugStores Co., Ltd.
3,405.00
-59.44
-1.72%
HUGroup Holdings Corporate Events
H.U. Group Launches ¥5 Billion Share Buyback to Boost Shareholder Returns
May 14, 2026
H.U. Group Holdings has approved a share buyback program as part of its five-year medium-term management plan, which it characterizes as an Investment Harvesting Phase focused on enhancing shareholder returns. The company targets a 6% Dividend on ...
H.U. Group Lifts Earnings, Keeps Dividend Steady as It Eyes Higher Sales in FY2027
May 14, 2026
H.U. Group Holdings reported a 1.8% rise in net sales to ¥247.4 billion for the year to March 31, 2026, with operating profit surging 81.0% to ¥4.8 billion and profit attributable to owners of parent climbing 147.1% to ¥6.8 billion,...
H.U. Group Revamps Board Lineup at Key Subsidiary SRL
Apr 24, 2026
H.U. Group Holdings, Inc. has approved a slate of director and auditor nominees for its key subsidiary SRL, Inc., to be put before shareholders at ordinary general meetings on June 16, 2026. The move reflects routine governance renewal, with both ...
H.U. Group Revamps Executive Team, Adds New R&D Chief
Apr 24, 2026
H.U. Group Holdings has announced a post–annual meeting reshuffle of its executive officer lineup, reaffirming Representative Executive Officer, President and Group CEO Goki Ishikawa and several other senior leaders in their current roles. T...
H.U. Group Overhauls Board, Nominates CEO Ishikawa and New Outside Directors
Apr 24, 2026
H.U. Group Holdings, Inc. has announced a slate of director nominees to be submitted to its 76th Ordinary General Meeting of Shareholders on June 16, 2026, where board changes will be formally decided. The list includes the new appointment of Repr...
H.U. Group Flags Increase in Stake by U.S. Institutional Investor GMO
Feb 27, 2026
H.U. Group Holdings has disclosed a change in its major shareholder following the submission of a large shareholding change report to the Kanto Local Finance Bureau. U.S.-based investment advisory firm Grantham Mayo, Van Otterloo Co, LLC (GMO) in...
H.U. Group Reshapes Top Management, Elevates New CEO and Executive Team
Feb 27, 2026
H.U. Group Holdings announced a broad reshuffle of executive officers effective April 1, 2026, including appointing Managing Executive Officer Goki Ishikawa as Representative Executive Officer, President and Group CEO, while current Chairman, Pres...
H.U. Group to Dispose of Treasury Shares for Expanded Stock Compensation Trusts
Feb 27, 2026
H.U. Group Holdings has approved the disposal of 1.12 million treasury shares, worth about JPY 3.69 billion at the previous day’s closing price, to fund stock-based compensation for executives and select employees via trust structures. The d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.